OPTICORE™, an innovative and accurate colonic targeting technology.Inflammatory bowel disease (IBD) is a debilitating condition, estimated to affect 7 million people worldwide.  Here, we describe an innovative colonic targeting concept, OPTICORE™ coating technology.  OPTICORE™ combines two release triggers (pH and enzyme: Phloral™) in the outer layer, with an inner layer promoting a release acceleration mechanism (Duocoat™).  Therefore, OPTICORE™ technology is designed to offer significant advantages over standard enteric coatings, particularly allowing for more accurate colonic drug delivery in ulcerative colitis patients.
OPTICORE
OPTICORE™, an innovative and accurate colonic targeting technology.Inflammatory bowel disease (IBD) is a debilitating condition, estimated to affect 7 million people worldwide.  Here, we describe an innovative colonic targeting concept, OPTICORE™ coating technology.  OPTICORE™ combines two release triggers (pH and enzyme: Phloral™) in the outer layer, with an inner layer promoting a release acceleration mechanism (Duocoat™).  Therefore, OPTICORE™ technology is designed to offer significant advantages over standard enteric coatings, particularly allowing for more accurate colonic drug delivery in ulcerative colitis patients.
OPTICORE
OPTICORE™, an innovative and accurate colonic targeting technology.Inflammatory bowel disease (IBD) is a debilitating condition, estimated to affect 7 million people worldwide.  Here, we describe an innovative colonic targeting concept, OPTICORE™ coating technology.  OPTICORE™ combines two release triggers (pH and enzyme: Phloral™) in the outer layer, with an inner layer promoting a release acceleration mechanism (Duocoat™).  Therefore, OPTICORE™ technology is designed to offer significant advantages over standard enteric coatings, particularly allowing for more accurate colonic drug delivery in ulcerative colitis patients.
OPTICORE
OPTICORE™, an innovative and accurate colonic targeting technology.Inflammatory bowel disease (IBD) is a debilitating condition, estimated to affect 7 million people worldwide.  Here, we describe an innovative colonic targeting concept, OPTICORE™ coating technology.  OPTICORE™ combines two release triggers (pH and enzyme: Phloral™) in the outer layer, with an inner layer promoting a release acceleration mechanism (Duocoat™).  Therefore, OPTICORE™ technology is designed to offer significant advantages over standard enteric coatings, particularly allowing for more accurate colonic drug delivery in ulcerative colitis patients.
OPTICORE
OPTICORE™, an innovative and accurate colonic targeting technology.Inflammatory bowel disease (IBD) is a debilitating condition, estimated to affect 7 million people worldwide.  Here, we describe an innovative colonic targeting concept, OPTICORE™ coating technology.  OPTICORE™ combines two release triggers (pH and enzyme: Phloral™) in the outer layer, with an inner layer promoting a release acceleration mechanism (Duocoat™).  Therefore, OPTICORE™ technology is designed to offer significant advantages over standard enteric coatings, particularly allowing for more accurate colonic drug delivery in ulcerative colitis patients.
OPTICORE